In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 386, Issue 3, 2013, Pages 247-253

  Hatanaka, Toshiki ^a   Ukai, Masashi ^a   Watanabe, Mai ^a   Someya, Akiyoshi ^a   Ohtake, Akiyoshi ^a   Suzuki, Masanori ^a   Ueshima, Koji ^a   Sato, Shuichi ^a   Sasamata, Masao ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

3 Adrenoceptor agonist; Cerebral infarcted rat; Mirabegron; Overactive bladder

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; CYCLIC AMP; ISOPRENALINE; MIRABEGRON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER MUSCLE; BRAIN INFARCTION; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MICTURITION; NONHUMAN; OVERACTIVE BLADDER; RAT; SHAM PROCEDURE;

ACETANILIDES; ADRENERGIC BETA-3 RECEPTOR AGONISTS; ANIMALS; CEREBRAL INFARCTION; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MUSCLE, SMOOTH; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, BETA-3; THIAZOLES; TRANSFECTION; URINARY BLADDER; URINARY BLADDER, OVERACTIVE;

EID: 84877894605     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-012-0821-4     Document Type: Article

References (34)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Kerrebroeck PV, Victor A, Wein A (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167-178
2. Andersson K-E, Arner A (2004) Urinary bladder contraction and relaxation physiology and pathophysiology. Physiol Rev 84:935-986
3. Athanasopoulos A, Giannitsas K (2011) An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. Adv Urol 816342
4. 3-adrenoceptor agonist in patients with overactive bladder (OAB). Eur Urol Suppl 9:249
5. de Groat WC, Yoshimura N (2001) Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol 41:691-721
6. 3 Adrenoceptor selectivity of the dioxolane dicarboxylate phenethanolamines. J Pharmacol Exp Ther 269:1000-1006
7. 3-adrenoceptor in human and rat detrusor muscle. J Urol 161:680-685
8. Griffiths DJ, McCracken PN, Harrison GM, Gormley EA, Moore K, Hooper R, McEwan AJB, Triscott J (1994) Cerebral aetiology of urinary urge incontinence in elderly people. Age Ageing 23:246-250
9. Hegde SS, Mammen M, Jasper JR (2004) Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies. Curr Opin Investig Drugs 5:40-44
10. 3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 126:819-825
11. Igawa Y, Aizawa N, Homma Y (2010) Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder. Korean J Urol 51(12):811-818
12. Ishiura Y (1996) Experimental study of voiding dysfunction induced by cerebral infarction in rats. Jpn J Urol 87:1221-1230
13. 3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol 168:1247-1252
14. Khan Z, Starer P, Yang WC, Bhola A (1990) Analysis of voiding disorders in patients with cerebrovascular accidents. Urology 35:265-270
15. Khullar V, Cambronero J, Stroberg P, Angulo J, Boerrigter P, Blauwet MB, Wooning M (2011) The efficacy and tolerability of mirabegron in patients with overactive bladder - results from a European-Australian Phase III trial. Eur Urol Suppl 10:278-279
16. Liberman JN, Hunt TL, Stewart WF, Wein A, Zhou Z, Herzog AR, Lipton RB, Diokno AC (2001) Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community based survey. Urology 57:1044-1050
17. 3-adrenergic receptors: differential agonist activation of recombinant receptors in Chinese hamster ovary cells. Mol Pharmacol 42:634-637
18. Longa EZ, Weinstein PR, Carlson S, Cummins R (1989) Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20:84-91
19. Madersbacher H, Halaska M, Voigt R, Höfner K (1999) A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 84:646-651
20. Michel MC, Sand C (2009) Effect of pre-contraction on β-adrenoceptor-mediated relaxation of rat urinary bladder. World J Urol 27:711-715
21. Michel MC, Ochodnicky P, Homma Y, Igawa Y (2011) β-Adrenoceptor agonist effects in experimental models of bladder dysfunction. Pharmacol Ther 131:40-49
22. Nakada Y, Yokoyama O, Komatsu K, Kodama K, Yotsuyanagi S, Niikura S, Nagasaka Y, Namiki M (2000) Effects of aniracetam on bladder overactivity in rats with cerebral infarction. J Pharmacol Exp Ther 293:921-928
23. Nitti V, Herschorn S, Auerbach S, Ayers M, Lee M, Martin N (2011) The efficacy and safety of mirabegron in patients with overactive bladder syndrome - results from a North-American Phase III trial. Eur Urol Suppl 10:278
24. Pehrson R, Stenman E, Andersson K-E (2003) Effects of tramadol on rat detrusor overactivity induced by experimental cerebral infarction. Eur Urol 44:495-499
25. Suzuki M, Ohtake A, Yoshino T, Yuyama H, Hayashi A, Ukai M, Okutsu H, Noguchi Y, Sato S, Sasamata M (2005) Effect of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infarcted rats. Eur J Pharmacol 512:61-66
26. 3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642-647
27. 3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther 288:1367-1373
28. Tsuchida S, Noto H, Yamaguchi O, Itoh M (1983) Urodynamic studies on hemiplegic patients after cerebrovascular accident. Urology 21:315-318
29. Uchida H, Shishido H, Nomiya M, Yamaguchi O (2005) Involvement of cyclic AMP-dependent and -independent mechanisms in the relaxation of rat detrusor muscle via β-adrenoceptors. Eur J Pharmacol 518:195-202
30. Wagg A, Compion G, Fahey A, Siddiqui E (2012) Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. doi: 10.1111/j.1464-410X.2012.11023.x
31. 3-adrenoceptors in human detrusor muscle. Urology 59(Suppl 5A):25-29
32. Yamazaki Y, Takeda H, Akahane M, Igawa Y, Nishizawa O, Ajisawa Y (1998) Species differences in the distribution of β-adrenoceptor subtypes in bladder smooth muscle. Br J Pharmacol 124:593-599
33. Yokoyama O, Yoshiyama M, Namik M, de Groat WC (1999) Glutamatergic and dopaminergic contributions to rat bladder hyperactivity after cerebral artery occlusion. Am J Physiol Regul Integr Comp Physiol 276:935-942
34. Yokoyama O, Yoshiyama M, Namiki M, de Groat MC (2002) Changes in dopaminergic and glutamatergic excitatory mechanisms of micturition reflex after middle cerebral artery occlusion in conscious rats. Exp Neurol 173:129-135